This trial is evaluating whether Temanogrel will improve 2 primary outcomes and 6 secondary outcomes in patients with Microvascular Obstruction (MVO). Measurement will happen over the course of Baseline (prior to administration of study treatment) to Post-PCI on Day 1.
This trial requires 99 total participants across 3 different treatment groups
This trial involves 3 different treatments. Temanogrel is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"The mvo is a rare finding in the kidney. More detailed studies are needed to define the pathophysiology, clinical significance and differential diagnosis of mvo in the kidney." - Anonymous Online Contributor
"It is probable that mvo causes more damage to the organ than blood loss and is, therefore, an important risk factor for acute kidney injury (AKI) after cardiac surgery." - Anonymous Online Contributor
"Microvascular obstruction (MVO) of the brain, also known as microinfarction, has a variety of causes. In addition, MVO can result in a wide range of symptoms, including headaches, visual changes, and changes in mood. Tissue plasminogen activator (tPA) infusion, intravenous rtPA, and intra-arterial thrombolysis with a microcatheter and microinfusion pump are common treatments for MVO. However, because many of the symptoms depend on the severity of MVO and the patient's preexisting health, it is often difficult to attribute specific symptoms to MVO treatment versus other causes." - Anonymous Online Contributor
"Many children with mvo demonstrated marked deterioration in their hemodynamics or function over a mean period of 6 yr despite ongoing medical treatment. At midterm follow-up these deteriorations remained more pronounced, with additional deterioration in the cerebral microcirculation. We conclude that the resolution of MVO following endovascular treatment does not necessarily mean clinical remission." - Anonymous Online Contributor
"The rate of mvo in the US is 0.45 per 100,000 population per year. This translates to 0.14 percent of men and women in the country." - Anonymous Online Contributor
"We did not identify significant difference in the prevalence of acute ischemic lesions between patients with and without microvascular obstruction. However, the findings of the present study demonstrated that both patients with and without macrothrombi had more hemorrhagic lesions than patients without acute ischemic lesions. Patients with microthrombi may need special attention to hemorrhagic manifestations and microvascular patency. Furthermore, evaluation of the severity of these lesions may be useful in predicting the severity of stroke and outcome." - Anonymous Online Contributor
"When prescribing the antiplatelet agents as part of the secondary prophylaxis after THA/TKA, our study showed that, when compared with other studies, a less frequent, more brief hospital stay and the early discontinuation of one of the antiplatelet agents may be important to consider." - Anonymous Online Contributor
"We found evidence for an over-representation of MVO in families of children with RPAI. This may be explained with the common occurrence of RPAI and MVO in the first degree relatives of the children with RPAI. Given the high prevalence of MVO in RPAI, it must be addressed in future families with RPAI." - Anonymous Online Contributor
"Microvascular obstruction in a patent ductus arteriosus (PDA) represents an extremely rare occurrence (<1%). Therefore, the overall incidence of this complication is not known. The treatment of choice was open correction of vascular obstruction with excision of the ductus arteriosus in patients at higher risk of complications during operative time, postoperatively and at long-term follow-up. Survival of these patients was improved when they entered a clinical trial (P = 0.016) and there was a significant (P < 0.001) improvement in their functional status at long-term compared to patients who received nonoperative treatment and did not enter a clinical trial (P = 0.056)." - Anonymous Online Contributor
"MVO is typically the result of a number of factors, including the following. Primary etiologies include thromboembolic events, myocardial infarction, and arterial stenosis. Secondary etiologies include atrial fibrillation, hypertension, cardiac valve disorders, systemic emboli, thrombophilia states, vascular diseases, tumors, infiltrates, infiltrates or abscess, and amyloidosis. Other causes not mentioned can occur, such as atherosclerosis, and hyperglycemia. MVO also can be caused by the obstruction of coronary vessels and systemic thromboemboli. A specific etiology can be demonstrated in less than 50% of cases of MVO." - Anonymous Online Contributor
"These data suggest that the improvement in quality of life following treatment with temanogrel may be associated with the reduction in the rate of heart failure hospital admission in patients with microvascular obstruction." - Anonymous Online Contributor